<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829916</url>
  </required_header>
  <id_info>
    <org_study_id>20-ROS-04</org_study_id>
    <nct_id>NCT04829916</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery</brief_title>
  <official_title>A Phase 1b, Randomised, Double-Blind, Parallel Treatment Group Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RMC-035 in Subjects Undergoing Non-Emergent On-Pump Coronary Artery Bypass Graft and/or Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guard Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guard Therapeutics AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of&#xD;
      RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing&#xD;
      cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study with two parallel treatment groups where subjects are randomized to receive&#xD;
      RMC-035 or a matching placebo in a double-blind fashion. The study will comprise of a&#xD;
      screening visit, followed by CABG and/or valve replacement on Day 1, double-blind treatment&#xD;
      period and a follow-up period up to Day 30.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nature, frequency and severity of AEs</measure>
    <time_frame>Baseline through day 30</time_frame>
    <description>• To evaluate the safety and tolerability of RMC-035 in subjects undergoing non-emergent, on-pump Coronary Artery Bypass Graft (CABG) and/or valve surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Blood samples will be taken pre-dose and up to 48 hours after start of Dose 1</time_frame>
    <description>Analysis of RMC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Blood samples will be taken pre-dose and up to 48 hours after start of Dose 1</time_frame>
    <description>Analysis of RMC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>Blood samples will be taken pre-dose and up to 48 hours after start of Dose 1</time_frame>
    <description>Analysis of RMC-035</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acute Kidney Injury (AKI)</condition>
  <arm_group>
    <arm_group_label>RMC-035</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RMC-035 intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo solution intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-035</intervention_name>
    <description>Multiple dosing during 48 hours following cardiac surgery</description>
    <arm_group_label>RMC-035</arm_group_label>
    <other_name>Solution for injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple dosing during 48 hours following cardiac surgery</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Solution for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Female and male subjects with an age ≥18 years&#xD;
&#xD;
          -  Subject is scheduled for non-emergent (elective) CABG and/or valve surgery (single or&#xD;
             multiple valves) with use of cardiopulmonary bypass (CPB)&#xD;
&#xD;
          -  Subject has at least ONE of the following risk factors for AKI at screening:&#xD;
&#xD;
               -  History of LVEF &lt;35% for at least 3 months prior to screening assessed by either&#xD;
                  echocardiography, cardiac MRI or nuclear scan.&#xD;
&#xD;
               -  History of previous open chest cavity cardiac surgery with or without CPB&#xD;
&#xD;
               -  Confirmed diagnosis of type 2 diabetes (T2DM) at least 3 months prior to&#xD;
                  screening AND ongoing treatment with an approved anti-diabetic drug&#xD;
&#xD;
               -  Age ≥70 years&#xD;
&#xD;
               -  Documented history of heart failure NYHA class II or higher for at least 3 months&#xD;
                  or longer at screening&#xD;
&#xD;
               -  Documented history of previous AKI before date of screening independent of the&#xD;
                  etiology of AKI&#xD;
&#xD;
               -  Documented history of anemia with hemoglobin ≤ 11 g/dL (≤6.8 mmol/L) for at least&#xD;
                  3 months prior to screening&#xD;
&#xD;
               -  Documented history of albuminuria, defined as UACR &gt;30 mg/g or &gt; 30 mg/24 hour in&#xD;
                  a 24-hour urine collection.&#xD;
&#xD;
               -  eGFR is ≤ 60 mL/min/1.73 m2 using the Chronic Kidney Disease - Epidemiology&#xD;
                  Collaboration (CKD-EPI) equation&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) is &lt;30 mL/min/1.73 m2 using the Chronic&#xD;
             Kidney Disease - Epidemiology Collaboration (CKD-EPI) equation at screening or at&#xD;
             baseline&#xD;
&#xD;
          -  Subject has surgery scheduled to be performed without CPB (&quot;off-pump&quot;)&#xD;
&#xD;
          -  Subject has surgery scheduled for aortic dissection&#xD;
&#xD;
          -  Subject is scheduled for CABG and/or valve surgery combined with additional&#xD;
             non-emergent cardiac surgeries, e.g. for atrial fibrillation ablation&#xD;
&#xD;
          -  Subject is scheduled to undergo trans catheter aortic valve implantation (TAVI) or&#xD;
             trans catheter aortic valve replacement (TAVR), or single vessel off-pump surgeries or&#xD;
             left ventricular device (LVAD) implantation&#xD;
&#xD;
          -  Subject has a requirement for any of the following within one week prior to surgery:&#xD;
             defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, other forms&#xD;
             of mechanical circulatory support (MCS) (Note: The prophylactic insertion of an IABP&#xD;
             preoperatively for reasons not related to existing LV pump function is not&#xD;
             exclusionary)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Agervald, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Guard Therapeutics AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Münster University Hospital</name>
      <address>
        <city>Münster</city>
        <zip>DE-481 49</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

